Kofimi Technology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kofimi Technology is a private, pre-revenue medical device company spun out of Tufts University, focused on eliminating racial bias in pulse oximetry. Its core innovation, the ChromaSense™ device, leverages advanced semiconductor technology and AI signal processing to deliver accurate readings irrespective of skin tone, motion, or perfusion. The company is targeting both clinical and home-care markets, including in-hospital monitoring, telehealth, chronic disease management, and newborn screening, and is currently advancing through regulatory and manufacturing milestones.

CardiovascularPulmonologyPediatricsSleep Medicine

Technology Platform

Proprietary integration of advanced semiconductor-based optical sensing hardware and AI/machine learning signal processing software designed for bias-free, medical-grade vital sign measurement.

Opportunities

The urgent, FDA-acknowledged need for equitable pulse oximetry creates a compelling market entry point for a superior solution.

The growing telehealth and remote patient monitoring markets offer expansive channels for a cloud-connected, accurate device.

Regulatory shifts and increased focus on health equity could drive rapid adoption and potentially favorable reimbursement pathways.

Risk Factors

Failure to obtain FDA clearance is an existential risk.

The company must compete against entrenched, low-cost incumbents in a price-sensitive healthcare market.

Clinical validation in larger, diverse populations is required to definitively prove superiority and drive widespread clinical adoption.

Competitive Landscape

Kofimi competes against large, established players like Masimo (a leader in signal processing), Philips, Medtronic, and Nonin, as well as numerous low-cost consumer device manufacturers. Its differentiation is a focused claim of bias-free accuracy across skin tones, a niche not fully addressed by current market leaders, though some are developing their own solutions in response to the bias issue.

More companies in United States →